Delphine Magis

ORCID: 0000-0002-4392-9413
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Migraine and Headache Studies
  • Trigeminal Neuralgia and Treatments
  • Transcranial Magnetic Stimulation Studies
  • Sympathectomy and Hyperhidrosis Treatments
  • Vestibular and auditory disorders
  • Functional Brain Connectivity Studies
  • Ophthalmology and Eye Disorders
  • Pain Management and Treatment
  • Vagus Nerve Stimulation Research
  • Laser Applications in Dentistry and Medicine
  • Olfactory and Sensory Function Studies
  • Pain Mechanisms and Treatments
  • Psychosomatic Disorders and Their Treatments
  • EEG and Brain-Computer Interfaces
  • Biochemical effects in animals
  • Photoreceptor and optogenetics research
  • Botulinum Toxin and Related Neurological Disorders
  • Mitochondrial Function and Pathology
  • Genetic Neurodegenerative Diseases
  • Hallucinations in medical conditions
  • Cardiac Arrhythmias and Treatments
  • Dementia and Cognitive Impairment Research
  • Neurological disorders and treatments
  • Cardiovascular Syncope and Autonomic Disorders
  • Neurological Complications and Syndromes

University of Liège
2011-2024

Centre hospitalier régional de la Citadelle
2011-2024

CHR Verviers
2020-2024

American Headache Society
2020

New York Proton Center
2020

University Radiology
2020

Centre Hospitalier Universitaire de Liège
2010-2019

Centre Hospitalier Chrétien
2019

Fondazione G.B. Bietti
2007-2016

University of Copenhagen
2015

Riboflavin, which improves energy metabolism similarly to coenzyme Q10 (CoQ10), is effective in migraine prophylaxis. We compared CoQ10 (3 × 100 mg/day) and placebo 42 patients a double-blind, randomized, placebo-controlled trial. was superior for attack-frequency, headache-days days-with-nausea the third treatment month well tolerated; 50%-responder-rate attack frequency 14.4% 47.6% (number-needed-to-treat: 3). efficacious tolerated.

10.1212/01.wnl.0000151975.03598.ed article EN Neurology 2005-02-22

To assess efficacy and safety of trigeminal neurostimulation with a supraorbital transcutaneous stimulator (Cefaly, STX-Med., Herstal, Belgium) in migraine prevention.This was double-blinded, randomized, sham-controlled trial conducted at 5 Belgian tertiary headache clinics. After 1-month run-in, patients least 2 attacks/month were randomized 1:1 to verum or sham stimulation, applied the daily for 20 minutes during 3 months. Primary outcome measures change monthly days 50% responder...

10.1212/wnl.0b013e3182825055 article EN Neurology 2013-02-07

Background Chronic cluster headache (CH) is a debilitating disorder for which few well-controlled studies demonstrate effectiveness of available therapies. Non-invasive vagus nerve stimulation (nVNS) was examined as adjunctive prophylactic treatment chronic CH. Methods PREVA prospective, open-label, randomised study that compared nVNS ( n = 48) with standard care (SoC) alone (control 49)). A two-week baseline phase followed by four-week (SoC plus vs control) and extension nVNS). The primary...

10.1177/0333102415607070 article EN cc-by-nc Cephalalgia 2015-09-21

The medical treatment of patients with chronic primary headache syndromes (chronic migraine, tension-type headache, cluster hemicrania continua) is challenging as serious side effects frequently complicate the course and some may be even medically intractable. When a definitive lack responsiveness to conservative treatments ascertained medication overuse excluded, neuromodulation options can considered in selected cases. Here, various invasive non-invasive approaches, such hypothalamic deep...

10.1186/1129-2377-14-86 article EN cc-by The Journal of Headache and Pain 2013-10-21

Abstract Background Occipital nerve stimulation (ONS) has raised new hope for drug-resistant chronic cluster headache (drCCH), a devastating condition. However its mode of action remains elusive. Since the long delay to meaningful effect suggests that ONS induces slow neuromodulation, we have searched changes in central pain-control areas using metabolic neuroimaging. Methods Ten drCCH patients underwent an 18 FDG-PET scan after ONS, at delays varying between 0 and 30 months. All were...

10.1186/1471-2377-11-25 article EN cc-by BMC Neurology 2011-02-24

Transcutaneous supraorbital nerve stimulation (tSNS) with the Cefaly® device was recently found superior to sham for episodic migraine prevention in a randomized trial. Its safety and efficiency larger cohorts of headache sufferers general population remain be determined. The objective this study assess satisfaction 2,313 who rented 40-day trial period via Internet. Only subjects using specific anti-migraine drugs, thus most likely suffering from migraine, were included survey. Adverse...

10.1186/1129-2377-14-95 article EN cc-by The Journal of Headache and Pain 2013-12-01

(Headache 2011;51:1191-1201) Background.— Drug-resistant chronic cluster headache (drCCH) is a devastating condition for which various invasive therapeutic procedures have been tempted without any satisfactory effect. Recent studies suggest that occipital nerve stimulation (ONS) could be an efficient preventive treatment of drCCH. Objective.— We conducted prospective pilot trial ONS in 8 subjects suffering from drCCH with encouraging results at 15 months. However, on larger population...

10.1111/j.1526-4610.2011.01973.x article EN Headache The Journal of Head and Face Pain 2011-08-16

Abstract Background Preventive pharmacotherapy for migraine is not satisfactory because of the low efficacy/tolerability ratio many available drugs. Novel and more efficient preventive strategies are therefore warranted. Abnormal excitability cortical areas appears to play a pivotal role in pathophysiology. Transcranial direct current stimulation (tDCS) non-invasive safe technique that able durably modulate activity underlying cerebral cortex, being tested various medical indications. The...

10.1186/1129-2377-14-23 article EN cc-by The Journal of Headache and Pain 2013-03-11

The debate on the clinical definition of refractory Chronic Migraine (rCM) is still far to be concluded. importance create a framing these rCM patients resides in complete disability they show, high risk serious adverse events from acute and preventative drugs uncontrolled application therapeutic techniques not yet validated.The European Headache Federation Expert Group presents hereby updated criteria for this harmful subset headache disorders. This attempt wants first impulse towards...

10.1186/1129-2377-15-47 article EN cc-by The Journal of Headache and Pain 2014-08-28

Introduction Non-invasive vagus nerve stimulation (nVNS; gammaCore®) has the potential to prevent migraine days in patients with on basis of mechanistic rationale and pilot clinical data. Methods This multicentre study included a 4-week run-in period, 12-week double-blind period randomised treatment nVNS or sham, 24-week open-label nVNS. Patients were administer two 120-second stimulations bilaterally neck three times daily (6–8 hours apart). Results Of 477 enrolled patients, 332 comprised...

10.1177/0333102419876920 article EN cc-by-nc Cephalalgia 2019-09-15

Background Benefits of cervical non-invasive vagus nerve stimulation (nVNS) devices have been shown in episodic cluster headache and preliminarily suggested migraine, but direct evidence activation using such is lacking. Vagal somatosensory evoked potentials (vSEPs) associated with vagal afferent reported for invasive (iVNS) auricular stimulation. Here, we aimed to show characterise vSEPs nVNS. Methods were recorded 12 healthy volunteers who received nVNS over the nerve, bipolar...

10.1177/0333102417717470 article EN cc-by Cephalalgia 2017-06-26

Background and aim A recent sham-controlled trial showed that external trigeminal nerve stimulation (eTNS) is effective in episodic migraine (MO) prevention. However, its mechanism of action remains unknown. We performed 18-fluorodeoxyglucose positron emission tomography (FDG-PET) to evaluate brain metabolic changes before after eTNS migraineurs. Methods Twenty-eight individuals were recruited: 14 with MO 20 healthy volunteers (HVs). HVs underwent a single FDG-PET, whereas patients scanned...

10.1177/0333102416656118 article EN cc-by-nc Cephalalgia 2016-06-23

Between attacks, migraineurs lack habituation in standard visual evoked potentials (VEPs). Visual stimuli also evoke high-frequency oscillations the gamma band range (GBOs, 20-35 Hz) assumed to be generated both at subcortical (early GBOs) and cortical levels (late GBOs). The consecutive peaks of GBOs were analysed regarding amplitude six successive blocks 100 averaged pattern reversal (PR)-VEPs healthy volunteers interictally migraine with (MA) or without aura patients. Amplitude two early...

10.1111/j.1468-2982.2007.01466.x article EN Cephalalgia 2007-11-07

Habituation of the nociception-specific blink reflex (nBR) is reduced interictally in migraine patients. This could be related to habituation deficit evoked cortical responses, a reproducible abnormality which has familial character, or central trigeminal sensitization due repeated attacks. We compared nBR healthy volunteers devoid personal family history (HV), without aura patients (MO) and with first degree relatives (HV-F). elicited by stimulating right supraorbital region custom-built...

10.1093/brain/awl351 article EN Brain 2007-01-24

The interictal deficit of habituation to repetitive visual stimuli in migraine patients could be due deficient intracortical inhibition and/or low cortical pre-activation levels. Which these abnormalities contributes more the cannot determined with common methods used record transient responses. We investigated lateral cortex during cycle and healthy subjects by using differential temporal modulations radial windmill-dartboard (WD) or partial-windmill (PW) patterns. Transient (TR-VEP)...

10.1186/1129-2377-14-20 article EN cc-by The Journal of Headache and Pain 2013-02-28

Background.—Impaired mitochondrial phosphorylation potential may play a role in migraine pathogenesis. Metabolic enhancers, such as riboflavin or coenzyme Q, are effective prophylaxis and quasi‐devoid of adverse effects. Thioctic acid (‐lipoïc acid) is another substance known to enhance energy metabolism mitochondria be beneficial diabetic neuropathy. Objective.—After an open pilot study suggesting its therapeutic antimigraine potentials, we embarked therefore randomized controlled trial...

10.1111/j.1526-4610.2006.00626.x article EN Headache The Journal of Head and Face Pain 2006-11-17

<b>Objectives:</b> In migraine, an interictal reduction of mitochondrial energy metabolism and a preventive effect high-dose riboflavin were reported. To explore the relation between two, we tested if therapeutic response to is associated with specific DNA (mtDNA) haplogroups. We focused our attention on haplogroup H, which known differ from others in terms metabolism. <b>Methods:</b> Sixty-four migraineurs completed 4-month open trial (400 mg QD) genotyped blindly for mtDNA <b>Results:</b>...

10.1212/wnl.0b013e3181a41269 article EN Neurology 2009-05-04

Abstract Background Galcanezumab, a humanized monoclonal antibody that selectively binds to calcitonin gene-related peptide, has demonstrated significant reduction in monthly migraine headache days phase 2 and 3 trials. In these analyses, we aimed evaluate the safety tolerability of galcanezumab compared with placebo for prevention episodic or chronic migraine. Methods Data were integrated from three double-blind clinical studies up 6-month exposure group ( N = 1435), five 1-year...

10.1186/s12883-020-1609-7 article EN cc-by BMC Neurology 2020-01-17

Background.—Lack of habituation, as reported in migraine patients between attacks for evoked cortical responses, was also recently found the nociceptive blink reflex (nBR) mediated by brainstem neurons. It is not known if both brain stem and habituation deficits are correlated same patient, which would favor a common underlying mechanism. Objective.—To search intraindividual correlations pattern reversal‐visual potentials that nociception‐specific migraineurs healthy volunteers (HV)....

10.1111/j.1526-4610.2005.00271.x article EN Headache The Journal of Head and Face Pain 2005-11-01
Coming Soon ...